SANBIO
LIVE

Serial Number

79203359

Owner

SanBio Company Limited

Attorney

N. Alexander Nolte

Filing Date

Oct 26, 2016

Add to watchlist:

No watchlists yet
View on USPTO

SANBIO Trademark

Serial Number: 79203359 • Registration: 5377414

SANBIO is a trademark filed by SanBio Company Limited on October 26, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

SanBio Company Limited (8 trademarks)

8-1, Akashi-Cho

Entity Type: 03

Trademark Details

Filing Date

October 26, 2016

Registration Date

January 16, 2018

Published for Opposition

October 31, 2017

Goods & Services

Pharmaceutical, veterinary preparations and sanitary preparations for gene therapy for medical purposes; pharmaceutical, veterinary preparations and sanitary preparations for cell therapy for medical purposes; pharmaceutical, veterinary preparations and sanitary preparations for regenerative medicine for medical purposes; medicines for treating central nervous system diseases; pharmaceutical, veterinary preparations and sanitary preparations, namely, cells, stem cells and living cells for gene therapy for medical purposes; pharmaceutical, veterinary preparations and sanitary preparations, namely, cells, stem cells and living cells for cell therapy for medical purposes; pharmaceutical, veterinary preparations and sanitary preparations, namely, cells, stem cells and living cells for regenerative medicine for medical purposes

Testing, inspection, research, development and evaluation services for others in the fields of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals; consulting services in the field of pharmaceutical research and development; and testing, inspection, research, or development of pharmaceutical preparations for gene therapy, cell therapy, regenerative medicine and medicines for treating central nervous system diseases; conducting clinical trials for others in the field of pharmaceutical products, providing medical and scientific research information in the field of pharmaceutical products, and consulting services in the field of pharmaceutical product research and development; conducting clinical trials for others, providing medical and scientific research information in the field of clinical trials, and consulting services for others in the field of design, planning, and implementation project management of clinical trials; medical research, compiling data for research purposes in the field of medical consultancy, and providing medical research information in the field of pharmaceuticals, gene therapy, cell therapy for medical purposes, regenerative medicine and medicines for treating central nervous system diseases; scientific research and development, scientific research, analysis, and testing in the field of pharmaceutical product development, gene therapy development, cell therapy for medical purposes development, regenerative medicine development and central nervous system diseases therapy development, consulting services in the field of pharmaceutical product research and development, gene therapy research and development, cell therapy for medical purposes research and development, regenerative medicine research and development and central nervous system diseases therapy medicine research and development, and providing scientific research information in the field of pharmaceuticals, gene therapy, cell therapy regenerative medicine and central nervous system diseases therapy medicine

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jul 8, 2024 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jul 8, 2024 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 2, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Oct 24, 2023 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 16, 2023 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 15, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 20, 2018 FICS
FINAL DISPOSITION PROCESSED
Apr 20, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 16, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 16, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 31, 2017 NPUB
PUBLISHED FOR OPPOSITION
Oct 31, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Oct 29, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 11, 2017 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 11, 2017 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 11, 2017 OP2R
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 26, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 25, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 25, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 25, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 25, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 25, 2017 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 2, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 2, 2017 CRFA
ASSIGNED TO LIE
Aug 31, 2017 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 16, 2017 PARI
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 15, 2017 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 14, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 14, 2017 REAP
REFUSAL PROCESSED BY IB
Apr 15, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 28, 2017 RFCS
REFUSAL PROCESSED BY MPU
Mar 28, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 26, 2017 RFCR
NON-FINAL ACTION WRITTEN
Mar 25, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 21, 2017 MAFR
ASSIGNED TO EXAMINER
Mar 17, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 17, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 16, 2017 REPR